Who makes MM09 Mannosylated 5.000 subcutaneous?

MM09 Mannosylated 5.000 subcutaneous is developed by Inmunotek S.L..

What development phase is MM09 Mannosylated 5.000 subcutaneous in?

MM09 Mannosylated 5.000 subcutaneous is in Phase 2.

Last reviewed 2026-04-19 · How we verify

MM09 Mannosylated 5.000 subcutaneous

Inmunotek S.L. · Phase 2 active Biologic

At a glance

Generic name	MM09 Mannosylated 5.000 subcutaneous
Also known as	Manano
Sponsor	Inmunotek S.L.
Modality	Biologic
Phase	Phase 2

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Dose Finding for the Treatment of Rhinitis/Rhinoconjunctivitis Against Mite Allergy (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

MM09 Mannosylated 5.000 subcutaneous CI brief — competitive landscape report
MM09 Mannosylated 5.000 subcutaneous updates RSS · CI watch RSS
Inmunotek S.L. portfolio CI